Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.
Adolescent
Adrenal Cortex Hormones
/ therapeutic use
Adult
Age Factors
Aged
Child
Child, Preschool
Disability Evaluation
Female
Follow-Up Studies
Humans
Immunologic Factors
/ therapeutic use
Male
Middle Aged
Neuromyelitis Optica
/ epidemiology
Recovery of Function
Retrospective Studies
Severity of Illness Index
Time-to-Treatment
Treatment Outcome
Young Adult
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
08
08
2018
revised:
06
12
2018
accepted:
09
12
2018
pubmed:
17
12
2018
medline:
14
6
2019
entrez:
17
12
2018
Statut:
ppublish
Résumé
Neuromyelitis optica spectrum disorder (NMOSD) attacks lead to incremental loss of function of the optic nerves and spinal cord. The standard of care for treatment of acute attacks to mitigate damage is high dose corticosteroids and, if needed, plasma exchange. Although the inclination among clinicians is to treat relapses as soon as they start, there is no previously published evidence to conclude that earlier treatment with corticosteroids is more effective in the long term. In this study, we correlated neurological outcomes from acute NMOSD relapses with delay to treatment, as well as demographic and clinical characteristics that influence prognosis.
Identifiants
pubmed: 30554039
pii: S2211-0348(18)30538-8
doi: 10.1016/j.msard.2018.12.010
pmc: PMC6397696
mid: NIHMS1516785
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-63Subventions
Organisme : NIAID NIH HHS
ID : R01 AI130548
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier B.V.
Références
Neurology. 2007 Feb 20;68(8):603-5
pubmed: 17310032
Neurol Res Int. 2012;2012:460825
pubmed: 22363840
Mult Scler Int. 2012;2012:787630
pubmed: 22474589
Arch Ophthalmol. 2012 Jul;130(7):858-62
pubmed: 22776923
Mult Scler. 2013 Aug;19(9):1216-8
pubmed: 23263897
JAMA Neurol. 2014 Mar;71(3):324-30
pubmed: 24445513
Mult Scler. 2016 Feb;22(2):185-92
pubmed: 25921047
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Ann Neurol. 2016 Feb;79(2):206-16
pubmed: 26537743
Curr Treat Options Neurol. 2016 Jan;18(1):2
pubmed: 26705758
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-351
pubmed: 29030418
J Neurol Sci. 2018 Jan 15;384:96-103
pubmed: 29249387
Surg Neurol Int. 2018 Feb 23;9:48
pubmed: 29541489
Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504
pubmed: 30345331